Scientists at La Jolla Institute for Immunology (LJI) have tracked down the rare stem cells that generate neutrophils in human bone marrow. This research, published August 18, 2020, in Immunity, gives researchers a potential path for intervening in diseases where neutrophil development goes awry.
Mayo Clinic y sus colaboradores publicaron un trabajo aún preimpreso acerca de dos señales principales de eficacia que pueden informar sobre la terapia con plasma para pacientes de COVID-19 en futuros ensayos clínicos.
Russian researchers have developed a new method for assessing individual risks of intravascular platelet activation. The latter plays a crucial role in the development of various serious clinical situations such as heart attacks and strokes. The range of circumstances that may be associated with the development of intravascular coagulation is currently actively investigated worldwide. In particular, the onset of intravascular coagulation may be triggered by temporary spikes in blood pressure.
Mayo Clinic and collaborators have published a preprint that identifies two main signals of efficacy that can inform future clinical trials on plasma therapy on COVID-19 patients. The data are extracted from the Mayo-led national Expanded Access Program (EAP) for convalescent plasma for the treatment of hospitalized patients with COVID-19.
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
A simple blood test that does not require overnight fasting has been found to be an accurate screening tool for identifying youth at risk for type 2 diabetes and heart disease risk later in life.
Nanoparticles are actively employed in medicine as contrast agents as well as for diagnosis and therapy of various diseases. However, the development of novel multifunctional nanoagents is impeded by the difficulty of monitoring their blood circulation. Researches from the Moscow Institute of Physics and Technology, the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow Engineering Physics Institute, Prokhorov General Physics Institute of RAS, and Sirius University have developed a new noninvasive method of nanoparticle measurement in the bloodstream that boasts a high time resolution. This technique has revealed the basic parameters that affect particle lifetime in the bloodstream, which may potentially lead to discovery of new, more effective nanoagents to be used in biomedicine.
Nodify Lung™ testing helps reclassify risk of malignancy of nodules by identifying patients with a higher or lower risk than indicated by traditional risk assessment
Some people who feel dizzy or lightheaded when they stand up may have an increased risk of developing dementia years later, according to a new study published in the August 12, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology. The condition, called orthostatic hypotension, occurs when people experience a sudden drop in blood pressure when they stand up.
George Washington University researchers found five biomarkers associated with higher odds of clinical deterioration and death in COVID-19 patients. Published in Future Medicine, these findings will help physicians better predict outcomes for COVID-19 patients in the U.S.
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.
A new study shows how chronic psychological stress leads to painful vessel-clogging episodes—the most common complication of sickle-cell disease (SCD) and a frequent cause of hospitalizations. The findings, made in mice, show that the gut microbiome plays a key role in triggering those episodes and reveals possible ways to prevent them. The research was conducted by scientists at Albert Einstein College of Medicine and published online today in Immunity.
Johns Hopkins researchers have received $35 million in funding from the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the Defense Health Agency, for two nationwide clinical trials to test the effectiveness of a convalescent blood plasma outpatient treatment. The treatment is a transfusion of a blood product from COVID-19 survivors that contains antibodies that may help the patient’s immune system fight the virus.
COVID-19 may increase the risk of blot cots in women who are pregnant or taking estrogen with birth control or hormone replacement therapy, according to a new manuscript published in the Endocrine Society’s journal, Endocrinology.
Alzheimer’s Blood Test: An expert panel with WUSTL, RUPress: July 28, 3PM EDT
Two decades or more before symptoms arise, plaques of a sticky protein called amyloid begin forming in the brains of people later diagnosed with Alzheimer’s disease.
Researchers at Washington University School of Medicine in St. Louis have developed a technique to detect minute amounts of a protein fragment linked to Alzheimer’s disease in the blood. The study, which will be published July 28 in the Journal of Experimental Medicine (JEM), shows that levels of p-tau-217 are elevated during the early stages of Alzheimer’s disease and could lead to a simple blood test capable of diagnosing the neurodegenerative disorder years before any symptoms begin to appear.
Researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies into a single therapy and found, in studies in human cells and in mice, that the two together are more effective than either alone in treating certain blood cancers, such as leukemia.
Post-surgical bleeding is associated with more deaths than blood clots from surgery, according to a Vanderbilt University Medical Center study published in the journal Anesthesia & Analgesia.
A new study from scientists at the La Jolla Institute for Immunology (LJI) shows that a previously poorly understood enzyme actually inhibits inflammation in blood vessels. The research offers a potential path to treating DADA2, an inflammatory blood vessel disease in children that is similar to Kawasaki disease.
The U.S. is currently experiencing a devastating shortage of plasma, and those in need are being forced to skip necessary treatments or go without – a possibly fatal situation.
A new study led by Albert Einstein College of Medicine and Montefiore Health System confirms the findings of the large scale British trial of steroid use for COVID-19 patients and advances the research by answering several key questions: Which patients are most likely to benefit from steroid therapy? Could some of them be harmed? Can other formulations of steroids substitute for the agent studied in the British trial? The research was published today in the Journal of Hospital Medicine.
A new method for rapid and inexpensive analysis of the chemical composition of blood samples may hasten the early diagnosis of diseases. The first application to be tested will be the early detection of various cancerous tumors based on blood tests.
An international team of researchers has developed a non-invasive blood test that can detect whether an individual has one of five common types of cancers, four years before the condition can be diagnosed with current methods. The test detects stomach, esophageal, colorectal, lung and liver cancer. Called PanSeer, the test detected cancer in 91% of samples from individuals who had been asymptomatic when the samples were collected and were only diagnosed with cancer one to four years later.
Researchers at Joslin Diabetes Center have discovered that some benefits of aerobic exercise may be dampened by higher-than-normal blood sugar levels, and that this is independent of obesity and insulin levels in the blood.
Kony Chacon credits a century-old treatment now being used to help coronavirus patients fight off the infection – convalescent blood plasma transfusions – with helping her recover.
Cannabis appears to be a safe and potentially effective treatment for the chronic pain that afflicts people with sickle cell disease, according to a new clinical trial co-led by University of California, Irvine researcher Kalpna Gupta and Dr. Donald Abrams of UC San Francisco. The findings appear in JAMA Network Open.
Researchers have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available. A new study published in the journal Science Translational Medicine describes the drug and its delivery mechanisms and shows that the drug is also an effective treatment for heart attack in animal models.
The Anesthesia Quality Institute (AQI), a related organization of the American Society of Anesthesiologists (ASA), announced today a quality-driven initiative dedicated to further developing the National Anesthesia Clinical Outcomes Registry (NACOR), the largest anesthesia registry in the country. The initiative, supported by Edwards Lifesciences, represents a shared vision between AQI and Edwards to improve data collection and analysis, including new tracking and feedback of intraoperative hypotension (low blood pressure), to better inform future quality standards that can positively impact patient outcomes.
• Ensures close connection between patient and physician for remote hypertension monitoring • Complements Mount Sinai’s growing telehealth initiative • Medicare-covered and generally at no cost to patients, depending on coverage
Infusing umbilical cord blood – a readily available source of stem cells – safely and effectively treated 44 children born with various non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, MLD, and an array of immune deficiencies.
Moffitt Cancer Center researchers want to learn more about how PI3K inhibitor therapy works with the body’s immune system to determine if there are ways to predict or mitigate associated adverse effects. Their findings were published in the July 14 issue of Blood Advances, a journal of the American Society of Hematology.
Stay-at-home orders during the COVID-19 pandemic has resulted in an increased need for blood and platelets. Rutgers Cancer Institute expert shares why right now is an important time to donate blood to ensure a sufficient blood supply for patients in need.
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.
A research team is the first in Texas to investigate whether plasma from COVID-19 survivors can be used in outpatient settings to prevent the onset and progression of the virus in two new clinical trials at UTHealth.
Researchers at University of California San Diego School of Medicine and UC San Diego Health have launched a clinical trial to assess the safety and efficacy of convalescent plasma (CP) to prevent COVID-19 after a known exposure to the virus.
A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a blood test involving these vesicles might be used to diagnose cancer in the future, avoiding the need for invasive surgical biopsies.
A blood biomarker in people who have had concussions may be just as accurate at predicting the severity of the injury and how long it will last as biomarkers that are obtained through more expensive and invasive tests, according to a study published in the July 8, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
If you have sickle cell disease, you are at higher risk than the general population for severe complications from COVID-19.
New findings led by Yale Cancer Center researchers and experts across several medical specialties at Yale identify a leading mechanism behind the pathophysiology of Covid-19 and pinpoint a biological marker for the mechanism that may aid in treating these patients.
Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists. The researchers found that inflammatory proteins produced during infection significantly alter the function of platelets, making them “hyperactive” and more prone to form dangerous and potentially deadly blood clots.
Scientists have new evidence that overactive neutrophils--a common type of circulating immune cell--may drive the life-threatening blood clots and inflammation that occur in some patients with COVID-19.
An overactive defense response may lead to increased blood clotting, disease severity, and death from COVID-19. A phenomenon called NETosis—in which infection-fighting cells emit a web-like substance to trap invading viruses—is part of an immune response that becomes increasingly hyperactive in people on ventilators and people who die from the disease.
Kawasaki disease, sometimes called Kawasaki syndrome, is a serious inflammation of the blood vessels which affects young children, often under 5 years of age. Marked by fever, swelling and other symptoms, it can lead to coronary artery aneurysms in approximately 25% of cases if untreated.
Edward J. Benz, Jr., MD, President and CEO Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School, has received the 2020 ASH Award for Leadership in Promoting Diversity.
A new study by researchers at UCSF Benioff Children’s Hospitals and St. Jude Children’s Research Hospital has identified what they believe to be a key reason behind patients’ treatment-resistance in the rare inflammatory disorder HLH. The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.
Tickets are on sale now for a fun-filled evening of vasculitis awareness and entertainment. Don’t miss it!
New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center’s Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease (GVHD) during allogeneic blood/marrow transplant (BMT) — a potentially curative treatment for selected patients with hematologic disorders — can be decreased using an existing class of drugs called beta adrenergic agonists.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right